I think the phase II Dep doc trial will be a catalyst for potential takeover, which is a while off yet. Hopefully by then the share price is already multiples higher on the back of vivagel licensing / sales and more Dep phase I trials commencing.
The reduced side effects alone make SPL’s Dep technology a very attractive target. If the phase II trials continue to demonstrate reduced side effects and comparable or improved efficacy there will be numerous suitors and options. I hope we hold out and can licence out the DEP technology progressively for decades to come. But if our Dep technology is what many of us believe it to be, then I also want it progressed as quickly as possible, which may be better done with a large pharma.
In the end, there are many potential deal scenarios possible.
SPL Price at posting:
$1.46 Sentiment: Buy Disclosure: Held
